Rapid Ebola Virus Detection Assay Evaluated
|
By LabMedica International staff writers Posted on 17 Nov 2015 |
|
Image: The Diagnostics-in-a-Suitcase used to screen for Ebolavirus disease (Photo courtesy of Institut Pasteur, Dakar).
Ebolavirus (EBOV) infection is mainly diagnosed by various in-house and commercial real-time reverse transcriptase polymerase chain reaction (RT-PCR) assays used in up to 38 laboratories implemented at or close to Ebola treatment centers (ETC) in West Africa.
Transmission of Ebolavirus disease (EVD) occurs almost exclusively from human to human by direct contact with body fluids of symptomatic cases. Consequently, the control strategy for EVD epidemics relies on early identification of EBOV-infected patients and corpses for, respectively, isolation and safe burials.
An international team of scientists led by those at the Institut Pasteur de Dakar (Dakar, Senegal) evaluated a new nucleic acid extraction kit on sera and swabs in combination with an improved diagnostic reverse transcription recombinase polymerase amplification assay for the detection of Ebolavirus (EBOV-RT-RPA) that was compared in parallel to other methods. Serum samples from acute cases and cheek and tongue swabs from deceased were collected. In addition, following an upsurge of EVD cases connected to funeral rites, oral swabs from all deceased were tested at the morgue.
The extraction kit tested was the SpeedXtract Nucleic Acid Kit (SE), (Qiagen; Hilden, Germany). The W-PCR was performed on the SmartCycler (Cepheid; Sunnyvale, CA, USA) using the RNA Master Hybridisation Probes kit (Roche; Manheim, Germany). A mobile laboratory was used which consisted of a glovebox, a Diagnostics-in-a-Suitcase (DiaS), and a solar panel and power pack set. The RT-RPA was performed using a custom-made EBOV-specific exo RT kit with pellets containing optimized enzyme concentrations.
The EBOV-RT-RPA was evaluated in comparison to two real-time PCR assays. The prevalence of EBOV in the swabs tested was 12.9%. The day of death after onset of disease peaked at day 6 (range: 2 to14 days) in the group of 67 swab-positive deceased for whom disease symptoms were recorded. Of 928 post-mortem swabs, 120 tested positive, and the combined SE and EBOV-RT-RPA yielded a sensitivity and specificity of 100% in reference to one real-time RT-PCR assay. Another widely used real-time RT-PCR was much less sensitive than expected. Results were provided very fast within 30 to 60 minutes, and the field deployment of the mobile laboratory helped improve burial management and community engagement.
Related Links:
Institut Pasteur de Dakar
Qiagen
Cepheid
Transmission of Ebolavirus disease (EVD) occurs almost exclusively from human to human by direct contact with body fluids of symptomatic cases. Consequently, the control strategy for EVD epidemics relies on early identification of EBOV-infected patients and corpses for, respectively, isolation and safe burials.
An international team of scientists led by those at the Institut Pasteur de Dakar (Dakar, Senegal) evaluated a new nucleic acid extraction kit on sera and swabs in combination with an improved diagnostic reverse transcription recombinase polymerase amplification assay for the detection of Ebolavirus (EBOV-RT-RPA) that was compared in parallel to other methods. Serum samples from acute cases and cheek and tongue swabs from deceased were collected. In addition, following an upsurge of EVD cases connected to funeral rites, oral swabs from all deceased were tested at the morgue.
The extraction kit tested was the SpeedXtract Nucleic Acid Kit (SE), (Qiagen; Hilden, Germany). The W-PCR was performed on the SmartCycler (Cepheid; Sunnyvale, CA, USA) using the RNA Master Hybridisation Probes kit (Roche; Manheim, Germany). A mobile laboratory was used which consisted of a glovebox, a Diagnostics-in-a-Suitcase (DiaS), and a solar panel and power pack set. The RT-RPA was performed using a custom-made EBOV-specific exo RT kit with pellets containing optimized enzyme concentrations.
The EBOV-RT-RPA was evaluated in comparison to two real-time PCR assays. The prevalence of EBOV in the swabs tested was 12.9%. The day of death after onset of disease peaked at day 6 (range: 2 to14 days) in the group of 67 swab-positive deceased for whom disease symptoms were recorded. Of 928 post-mortem swabs, 120 tested positive, and the combined SE and EBOV-RT-RPA yielded a sensitivity and specificity of 100% in reference to one real-time RT-PCR assay. Another widely used real-time RT-PCR was much less sensitive than expected. Results were provided very fast within 30 to 60 minutes, and the field deployment of the mobile laboratory helped improve burial management and community engagement.
Related Links:
Institut Pasteur de Dakar
Qiagen
Cepheid
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Automated Clinical Chemistry Analyzer
Envoy 500+
Prefilled Tubes
Prefilled 5.0ml Tubes
Latest Microbiology News
- Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
- Proteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
- Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
- Portable Molecular Platform to Advance Point-of-Care Testing for Lassa Fever
- New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
- Study Highlights Need for Routine Hepatitis E Testing in Cirrhosis
- High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
- Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
- New Rapid Ebola Antigen Test Detects Infection at Point of Care
- Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
- Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
- Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
- Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
- CE-Marked Blood Assay Automates Tuberculosis Infection Testing
- Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
- Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
Channels
Clinical Chemistry
view channel
Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing
Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more
Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients
Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more
Molecular Diagnostics
view channel
Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy
Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more
Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings
Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read more
Hematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read more
Immunology
view channel
Study Reveals Viral Protein Driving COVID-19-Related Vascular Injury
Lingering symptoms after acute COVID-19 infection remain a clinical challenge, with many patients experiencing fatigue, cognitive problems, and cardiovascular complications months later.... Read more
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Pathology
view channel
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more
